Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: EPro who wrote (1944)	6/24/1999 12:56:00 PM
From: Don Dorsey	Read Replies (1) \| Respond to of 2135

EntreMed, Inc. Announces Licensing Agreement With Calbiochem-Novabiochem Corp. for the Sale of Research Grade Endostatin Protein and Angiostatin Protein Health/Medical Writers ROCKVILLE, Md.--(BW HealthWire)--June 24, 1999--EntreMed, Inc. (NASDAQ:ENMD) today announced the signing of a non-exclusive, worldwide licensing agreement with Calbiochem-Novabiochem Corp., of San Diego, CA (Calbiochem) under which Calbiochem will have the right to sell research grade Endostatin(TM) protein and Angiostatin(R) protein for non-commercial research purposes. In addition to the non-exclusive license to sell Endostatin(TM) protein and Angiostatin(R) protein, Calbiochem will sell research grade human recombinant Endostatin(TM) protein produced by EntreMed. Calbiochem will make royalty payments to EntreMed on all sales of both murine (mouse) and human Endostatin(TM) protein and Angiostatin(R) protein. EntreMed supports the scientific investigation of its product candidates, Endostatin(TM) protein and Angiostatin(R) protein, and therefore encourages the broad distribution of these proteins to scientific laboratories for non-commercial research purposes. Dr. Edward R. Gubish, Senior Vice President of Research and Development for EntreMed commented: "This licensing agreement will give research laboratories broader access to murine and recombinant human Endostatin(TM) protein and Angiostatin(R) protein which will expand the body of knowledge for these potent antiangiogenic agents. The material produced by EntreMed and sold through Calbiochem-Novabiochem is not suitable for human use and is not available for tests involving humans." Gubish continued, "We look forward to increased preclinical research publications on the efficacy of Endostatin(TM) protein and Angiostatin(R) protein as a result of worldwide access to our research grade material." Dr. John W. Holaday, EntreMed Chairman, President and Chief Executive Officer stated, "The licensing agreement between EntreMed and Calbiochem-Novabiochem is the second revenue-generating agreement that we have signed in the past six months. Proceeds from sales of research grade Endostatin(TM) protein and Angiostatin(R) protein will further assist us in expanding the successful internal discovery program now in place at EntreMed." In total, EntreMed owns, or has acquired, exclusive worldwide rights to over 250 US and foreign pending and issued patents relating to its core technologies. The Company will continue to vigorously protect its intellectual property against any commercial development of Endostatin(TM) protein and Angiostatin(R) protein. Rockville, MD-based EntreMed, Inc., The Angiogenesis Company(TM), is a leader in the field of antiangiogenesis research, which studies the inhibition of abnormal blood vessel growth recently associated with a broad range of diseases. The Company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at www.entremed.com.